#91 – Moonshot medicine, multi-cancer markers & respiratory revelations
The coffee break biotech roundup, by SomX.
Houston, we have a newsletter,
This week, a sugar matrix finally launches vaccines that can bypass the cold chain, MethylScan detects cancer and liver disease for less than the cost of an in-flight meal, Anthropic pays $400M to pull 8 months of stealth biology into its orbit, FebriDx clears for takeoff in 300,000 US outpatient clinics to curb unnecessary antibiotic prescribing, and human cells head to the moon to see how they hold up beyond Earth’s atmosphere.
Mission control, Dodo is over and out.
If there’s anything you’d like to see in future editions of Biotech Dodo, send us a message.
Discover 🔍
💉 New drying technique stabilises vital vaccines at room temperature (News Medical): Oxford engineers have validated MART, a room-temperature drying technique that locks proteins into a stable sugar-based matrix on cellulose fibres, neatly sidestepping the freezing that typically does for sensitive biologics. The process takes as little as 3hrs and requires no specialist equipment. Tested across four targets, including COVID-19 diagnostic reagents and growth factors, dried samples retained over 90% of their activity after 6 months at 25°C.
Our take: Cold chain failures waste billions of dollars’ worth of vaccines annually, with a human cost borne by children in regions like sub-Saharan Africa and South Asia, where cold chain infrastructure simply isn’t up to scratch. The problem has been thoroughly catalogued for decades and thoroughly not cracked. MART takes just a few hours and requires no specialist kit. For low-resource settings, the most useful tech is the one that actually makes it off the lorry.
🩸 Low-cost, single sample blood test detects different cancers, liver disorders, and other diseases (GEN): UCLA scientists have developed MethylScan, a blood test that reads DNA methylation patterns in cell-free DNA to sniff out multiple cancers, liver conditions, and organ abnormalities from a single sample. The method works by enzymatically stripping out background DNA from blood cells before sequencing. Across 1,061 patients, it achieved 63% overall cancer detection and 55% for early-stage disease, with 98% specificity, and a projected cost under $20 per sample.
Our take: Galleri, the market leader in multi-cancer detection, costs $949 and isn’t covered by most insurers. MethylScan’s rather more interesting trick is correctly classifying 85% of liver disease patients by type from the same blood draw, distinguishing viral hepatitis from metabolic disease without so much as a biopsy. At 55% early-stage sensitivity, it isn’t miles ahead of Galleri at 51% – suggesting detection is now the unsolved problem, not affordability.
💰 AI giant Anthropic leans into life sciences with $400M Coefficient Bio catch (BioSpace): The all-stock deal folds fewer than 10 people into Anthropic’s healthcare division, bolstering Claude Life Sciences – its biopharma-focused AI platform already used by Sanofi, Novo Nordisk, and AbbVie. Coefficient was founded just eight months ago by Nathan Frey and Samuel Stanton, both from Genentech’s Prescient Design computational drug discovery unit, and had been operating entirely in stealth.
Our take: That much money for an eight-month-old company with no disclosed product raises an eyebrow until you clock what Frey and Stanton built at Genentech – not AI wrappers bolted onto biology, but biological foundation models and protein design infrastructure from the architecture up. That calibre of talent is scarce, and Anthropic’s head of healthcare wants a meaningful percentage of all life science work running on Claude.
🪄 Lumos to access $1b US market with diagnostic device, raises $20m (The Australian): Australian diagnostics company Lumos has secured a CLIA waiver for FebriDx, its point-of-care test that distinguishes viral from bacterial respiratory infections. Previously confined to hospitals and laboratories, the waiver unlocks more than 300,000 outpatient locations, including physician offices, urgent care clinics, and pharmacy settings. The company has raised $20M to fund the US commercial rollout.
Our take: Antibiotic stewardship has spent decades drilling hospitals – the setting that accounts for a minority of prescribing. The bulk of inappropriate prescribing happens in outpatient settings where a clinician has minutes, no diagnostics, and a patient expecting a prescription. A CLIA waiver means FebriDx can now reach the GP surgeries and the pharmacy, the places unintentionally doing a lot of AMR damage.
And finally…
🚀 How NASA’s moon mission could help transform space medicine (Scientific American): NASA’s Artemis II mission is carrying AVATAR, an experiment using organs-on-a-chip – flash-drive-sized devices lined with living human cells that mimic specific organs. The chips contain bone marrow cells from the four Artemis II astronauts, matched against identical chips on Earth. After the mission, single-cell RNA sequencing will measure gene-level changes caused by deep space radiation and microgravity.
Our take: Organs-on-a-chip already sit in 17 of 25 top biopharma companies’ labs, valued for generating human biological data that animal models routinely get wrong. Deep space radiation and microgravity accelerate bone loss, suppress immunity, and damage DNA in ways that mirror accelerated disease states on Earth. That data, collected from astronauts’ own cells against matched Earth controls, is territory no laboratory has reached before.
Tune in 🎧
💊Novartis Buys Excellergy for $2B, Anthropic Vs. Pentagon, The Mansion Section: A condensed cut of TBPN’s live tech coverage, touching on Novartis’s latest acquisition, Anthropic’s Pentagon tensions, and real estate.
🩸This Startup Wants To Catch Cancer Before It Spreads: BillionToOne’s David Tsao and Oguzhan Atay trace the company’s path from prenatal cfDNA screening to early cancer detection, and what a $4B valuation means for the field.
🌕13 Minutes Presents: Artemis II: Tim Peake and Maggie Aderin-Pocock cover NASA’s first crewed lunar mission in over 50 years, with updates from Kennedy Space Centre and context on the geopolitics driving the new space race.
Apply ✍️
🔬 Entry Level - Clinical Research Associate, Medspace: New to clinical research? You’ll conduct site monitoring visits, verify source data against case report forms, review regulatory documents, and keep adverse event reporting on the right side of GCP.
💼 Head of R&D and Scientific Strategy, Rare Disease, Syneos Health: Keen to shape the scientific direction of a global CRO? Reporting to the CSO, you’ll lead cross-functional initiatives, drive thought leadership strategy, and represent rare disease capabilities in front of customers and C-suite.
🧪 Biotech Application Scientist, Axitan Research UK: Got a nose for formulation science? You’ll translate R&D concepts into scalable feed additive products across poultry, swine, and aquaculture, optimise performance at pilot scale, and feed findings into IP filings.
RSVP 📆
🇮🇹 16-17.04 | 16th International Conference on Biotechnology | Rome, Italy: Under the theme “Living Technologies for a Changing World: The Future Begins in Biotechnology,” this global meeting celebrates innovation where biology meets imagination, exploring how living systems can heal, adapt, and drive sustainable transformation across health, energy, and the environment.
💊 16.04 | Frontier Biotech Tables: From Signal to Drug | London, UK: This gathering unites biotech founders, frontier researchers, pharma dealmakers, and investors to dissect what’s really holding back translation, and how to unlock the next generation of ageing therapeutics.
🌱 21.04 | BioSolutions UK | London, UK: Discover how biology is driving real-world solutions to global challenges, and be part of the conversation that’s transforming the future of our planet. Whether you’re a startup, scale-up, investor, industrial leader, or policymaker, there’s something for everyone.
📑 29.04 | The Hardian Health Tech Summit | London, UK: The Hardian team will be joined by representatives from the MHRA, FDA, NICE, NHS leaders, and more across the healthtech world for real-world insight into regulation and market access in medical devices.
Got news, jobs or events you think are worth coo-ing over? Post an event here, or email us at biotechdodo@substack.com!
We’re SomX – a communications and creative agency trusted by biotech, pharma and healthtech pioneers. We craft strategy, content, PR and design that translate complex biology into compelling stories and investor‑ready excitement. Get in touch to amplify your science beyond the lab bench.